Get started
Savara, Inc.Savara, Inc.Savara, Inc.

Savara, Inc.

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Market insights

Savara, Inc. (SVRA) Advances Rare Lung Disease TherapySavara, Inc. (SVRA) is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Its lead program targets pulmonary alveolar proteinosis, aiming to improve lung function through a highly targeted inhaled biologic. Savara’s growth is driven by advancing clinical progress, strong support within the rare-disease community, and rising demand for innovative treatments that address serious unmet medical needs. On the chart, a confirmation bar with increasing volume signals bullish strength. The price has moved into the momentum zone after breaking above the .236 Fibonacci level. A trailing stop can be placed just below the .236 Fib using the Fibonacci snap tool, helping traders protect gains while staying positioned for further upside.
NASDAQ:SVRALong
by traderspro_charts
SVRA Breaking downSVRA had a major U-turn after it's last earnings report. It gave up the trend line again after initially losing badly on Apr 24 (which was a bad day for markets all around.) It has since developed quite the DTL, which is legit as distribution days are more volume heavy. Hoping to see it hit the DTL buffer as an entry, since the DTL is a little steep. That being said, if we breakdown,( break the tiny bear flag, break Friday LOD) I could see us riding the DTL to next leg with 3.50 as a first target. Stops are low 4.30's
NASDAQ:SVRAShort
by Shagoyev
$SVRA can rise in the next daysContextual immersion trading strategy idea. Savara Inc. operates as an orphan lung disease company. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,77; stop-loss — $1,54. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:SVRALong
by KozakHlib
2
SVRA BIO TECH LongSector: Health Technology Industry: Biotechnology Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX. Market Capitalization 115.522M Total Shares Outstanding (MRQ) 54.236M Net Debt (MRQ) -56.821M Total Assets (MRQ) 97.745M Revenue per Employee (TTM) 9518.5185 Free Cash Flow (TTM) -39.883M :(, but it's BIO and other indicators look good. Phase 2-3 trials, FDA looking at turning decision from June that scared off investors. Analyst upgrade to 7
NASDAQ:SVRALong
by happytrader1543
SVRA Break OutThe price took out 5 fibonacci levels (.61, .78, 1, 1.61, 2.61) yesterday with the candle gapping up big. It managed to break thru the descending weekly trend line to close just under the .78 level. Also the MACD is freshly crossed and the RSI is still cool especially considering the monster candle yesterday. I think this chart looks bullish AF and Im looking for a continuation. Resistance possible at 2.25. First target $2.71 and possibly back to recent highs.
NASDAQ:SVRALong
by Master_of_Fine_Charts
$SVRA Announces Closing of $130 Million Public OfferingSavara Announces Pricing of Public Offering of Common Stock $SVRA today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offered to certain existing investors pre-funded warrants to purchase an aggregate of 32,175,172 shares of common stock at a purchase price of $1.449 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. finance.yahoo.com Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option finance.yahoo.com
NASDAQ:SVRA
by AlenCiken
Option Traders Bet Big on Savara $svraInvestors in Savara Inc. need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today. Source Zacks Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, T.
NASDAQ:SVRALong
by RedHotStocks
$SVRA Much more upside in SAVARA Savara continues to rise afterhours in response to its announcement that the FDA has granted Breakthrough Therapy Designation (BTD) for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP). The last 45 mins of trading today seen huge buying and a 50% surge into the close. Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application. Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, T.
NASDAQ:SVRALong
by Bullishcharts
6
SAVARA inc breakout on FDA approvalSavara (NASDAQ:SVRA) is up 96% premarket in response to its announcement that the FDA has granted Breakthrough Therapy Designation (BTD) for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP). Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application. Seeking alpha Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, T.
NASDAQ:SVRALong
by DEXWireNews
1